StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)

Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –

Exelixis operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Exelixis's operating cash flow for the twelve months ending Oct 2, 2026 was $1.17B, up 48.3% year over year. For fiscal 2025 it was $884.27M, up 26.3% from the year before. The highest annual figure on record is $884.27M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Jan 2, 2026$884.27M+26.3%
FY2024Jan 3, 2025$699.97M+110.0%
FY2023Dec 29, 2023$333.32M-8.1%
FY2022Dec 30, 2022$362.61M-9.5%
FY2021Dec 31, 2021$400.80M+91.8%
FY2020Jan 1, 2021$208.98M-60.3%
FY2019Jan 3, 2020$526.96M+26.8%
FY2018Dec 28, 2018$415.72M+151.0%
FY2017Dec 29, 2017$165.61M-21.3%
FY2016Dec 31, 2016$210.40M–
FY2015Dec 31, 2015-$141.05M–
FY2014Dec 31, 2014-$235.41M–
FY2013Dec 31, 2013-$198.77M–
FY2012Dec 31, 2012-$123.15M–
FY2011Dec 31, 2011-$159.23M–
FY2010Dec 31, 2010-$101.05M–
FY2009Dec 31, 2009-$14.59M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Oct 2, 2026$279.96M-3.6%
Q2 FY2026Jul 3, 2026$307.74M+528.1%
Q1 FY2026Apr 3, 2026$251.85M+19.1%
Q4 FY2025Jan 2, 2026$333.52M+38.8%
Q3 FY2025Oct 3, 2025$290.32M+7.0%
Q2 FY2025Jul 4, 2025$48.99M-59.0%
Q1 FY2025Apr 4, 2025$211.44M+207.2%
Q4 FY2024Jan 3, 2025$240.26M+2172.9%
Q3 FY2024Sep 27, 2024$271.34M+131.2%
Q2 FY2024Jun 28, 2024$119.55M-1.2%
Q1 FY2024Mar 29, 2024$68.82M-18.5%
Q4 FY2023Dec 29, 2023$10.57M-85.7%
Q3 FY2023Sep 29, 2023$117.37M+6.6%
Q2 FY2023Jun 30, 2023$120.98M+288.6%
Q1 FY2023Mar 31, 2023$84.41M-42.9%
Q4 FY2022Dec 30, 2022$73.69M-23.6%
Q3 FY2022Sep 30, 2022$110.07M+32.1%
Q2 FY2022Jul 1, 2022$31.13M-82.8%
Q1 FY2022Apr 1, 2022$147.72M+273.6%
Q4 FY2021Dec 31, 2021$96.45M+189.7%
Q3 FY2021Oct 1, 2021$83.31M+364.4%
Q2 FY2021Jul 2, 2021$181.50M+78.5%
Q1 FY2021Apr 2, 2021$39.54M-29.5%
Q4 FY2020Jan 1, 2021$33.29M-78.9%
Q3 FY2020Oct 2, 2020$17.94M-76.3%
Q2 FY2020Jul 3, 2020$101.68M-22.8%
Q1 FY2020Apr 3, 2020$56.07M-65.3%
Q4 FY2019Jan 3, 2020$158.02M+51.1%
Q3 FY2019Sep 27, 2019$75.61M-54.1%
Q2 FY2019Jun 28, 2019$131.73M+76.9%
Q1 FY2019Mar 29, 2019$161.59M+125.0%
Q4 FY2018Dec 28, 2018$104.59M+96.0%
Q3 FY2018Sep 28, 2018$164.86M+335.4%
Q2 FY2018Jun 29, 2018$74.47M+1245.3%
Q1 FY2018Mar 30, 2018$71.81M+4.3%
Q4 FY2017Dec 29, 2017$53.35M-37.3%
Q3 FY2017Sep 30, 2017$37.87M–
Q2 FY2017Jun 30, 2017$5.54M–
Q1 FY2017Mar 31, 2017$68.86M–
Q4 FY2016Dec 31, 2016$85.11M–

More Exelixis figures

See a number that looks wrong?